Please use this identifier to cite or link to this item: https://scholarbank.nus.edu.sg/handle/10635/118793
Title: UTILITY OF PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS IN GASTROINTESTINAL CANCER
Authors: CHONG MEI LING
Keywords: PI3-kinase, gastric cancer, colorectal cancer, PIK3CA mutation, IGFBP3, biomarkers
Issue Date: 24-Jan-2014
Citation: CHONG MEI LING (2014-01-24). UTILITY OF PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS IN GASTROINTESTINAL CANCER. ScholarBank@NUS Repository.
Abstract: INHIBITION OF THE PHOSPHATIDYLINOSITOL-3-KINASE (PI3K) SIGNALLING PATHWAY IS A CANCER TREATMENT STRATEGY THAT HAS ENTERED INTO CLINICAL TRIALS FOR GC AND CRC PATIENTS. THE AIMS OF THIS STUDY WERE 1) TO CHARACTERISE INTER-ETHNIC FREQUENCIES AND CO-OCCURRENCE PATTERNS OF PROMINENT PI3K PATHWAY ABERRATIONS IN GC AND CRC, AND 2) TO IDENTIFY PREDICTIVE BIOMARKERS FOR PI3K INHIBITORS IN GC AND CRC CELLS. THE META-ANALYSIS INDICATED THAT EAST ASIAN AND CAUCASIAN GC PATIENTS DIFFER SIGNIFICANTLY IN THE FREQUENCIES OF PIK3CA EXON 9 AND EXON 20 MUTATIONS, PTEN DELETION AND PTEN LOSS, WHILE CRC PATIENTS DIFFERED FOR PTEN LOSS. HIGH STUDY HETEROGENEITY WAS OBSERVED FOR ALL ABERRATIONS EXCEPT PIK3CA MUTATIONS. ANALYSIS OF TUMOURS FROM EAST ASIAN PATIENTS REVEALED SIGNIFICANT DIFFERENCES BETWEEN GC AND CRC FOR THE FREQUENCIES OF PIK3CA AMPLIFICATION AND PTEN LOSS. ONCOCARTA ANALYSIS REVEALED THAT PIK3CA MUTATION WAS ASSOCIATED WITH INCREASED SENSITIVITY TO PI3K INHIBITORS, AND KRAS (G12V) MUTATION W
URI: http://scholarbank.nus.edu.sg/handle/10635/118793
Appears in Collections:Ph.D Theses (Open)

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
ChongML.pdf.pdf3.92 MBAdobe PDF

OPEN

NoneView/Download

Page view(s)

140
checked on Oct 23, 2020

Download(s)

58
checked on Oct 23, 2020

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.